Loading...
•
Jun 30
•/
Stevanato Group Q2 2025 Earnings Report
Stevanato Group reported revenue of €280.0 million for the second quarter of 2025, demonstrating an 8% increase in revenue, expanded margins, and maintained its fiscal year 2025 guidance.
Key Takeaways
Stevanato Group delivered a solid second quarter in 2025, with revenue increasing by 8% to €280.0 million, driven by strong performance in the Biopharmaceutical and Diagnostic Solutions (BDS) Segment. The company also expanded its gross profit and adjusted EBITDA margins, while maintaining its fiscal year 2025 guidance.
Revenue increased by 8% year-over-year to €280.0 million in Q2 2025, with high-value solutions accounting for 42% of total revenue.
Gross profit margin expanded by 210 basis points to 28.1%, and adjusted EBITDA margin increased by 240 basis points to 23.2%.
The Biopharmaceutical and Diagnostic Solutions (BDS) Segment saw a 10% revenue increase to €243.5 million, driven by high-value solutions.
The company maintained its fiscal year 2025 guidance for revenue, adjusted EBITDA, and adjusted diluted EPS, reflecting confidence in continued growth and operational efficiency.
Stevanato Group
Stevanato Group
Stevanato Group Revenue by Segment
Revenue by Segment
Biopharmaceutical & Diagnostic Revenue
CapyFin.comEngineering Revenue
CapyFin.com Forward Guidance
Stevanato Group is maintaining its fiscal year 2025 guidance, expecting continued revenue growth, strong adjusted EBITDA, and improved adjusted diluted EPS, driven by strategic investments and market trends.
Positive Outlook
- Maintaining fiscal 2025 revenue guidance in the range of €1.160 billion to €1.190 billion.
- Maintaining fiscal 2025 adjusted EBITDA guidance in the range of €288.5 million to €301.8 million.
- Maintaining fiscal 2025 adjusted diluted EPS guidance in the range of €0.50 to €0.54.
- Strategic capital investments are aligned to meet demand-driven needs in high-growth markets.
- Robust pipeline of long-term opportunities fueled by pharmaceutical innovation and the rise in biologics.
Challenges Ahead
- No specific negative forward guidance points were explicitly stated in the provided text.
- The company did not provide any updated negative outlooks or revised downward expectations.
- No specific risks or challenges for the upcoming periods were highlighted in the guidance section.
- No mention of potential impacts from global economic uncertainties or supply chain issues.
- No specific concerns regarding competitive pressures or regulatory changes were outlined.
Revenue & Expenses
Visualization of income flow from segment revenue to net income